NewsBenzingaアボット、VERITAS試験におけるAmulet 360左心耳閉鎖デバイスの1年間の結果を発表;データは、心臓弁膜症を原因としない心房細動患者において、左心耳の有意な閉鎖率と低い脳卒中発生率を示す アボット、VERITAS試験におけるAmulet 360左心耳閉鎖デバイスの1年間の結果を発表;データは、心臓弁膜症を原因としない心房細動患者において、左心耳の有意な閉鎖率と低い脳卒中発生率を示す Benzinga 2026.11.02 14:06 (GMT+0) Open on Benzinga Other news 'China Taps US AI Models To Train Homegrown Rivals As Chip Curbs Bite' - Reuters Exclusive 'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century' A-Share Close: ChiNext Index Down Over 1% After Intraday Reversal, More Than 4,100 Stocks Fall Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen Aytu BioPharma Stock Climbs 44% After-Hours: Here's Why Reported Earlier, MediaCo Holding Q3 EPS $(0.11) Up From $(0.22) YoY, Sales $28.600M Down From $35.398M YoY
'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century'
Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen
Reported Earlier, MediaCo Holding Q3 EPS $(0.11) Up From $(0.22) YoY, Sales $28.600M Down From $35.398M YoY